Journal: PLoS ONE

Article Title: Toll-Like Receptor 2 Induced Angiogenesis and Invasion Is Mediated through the Tie2 Signalling Pathway in Rheumatoid Arthritis

doi: 10.1371/journal.pone.0023540

Figure Lengend Snippet: Human dermal microvascular endothelial cell tubule formation on matrigel matrix following stimulation with Pam3CSK4 (1 ug/ml). (A) Representative image of baseline tube formation (left panel) and tube formation following stimulation with Pam3CSK4 (right panel). (B) Quantitative analysis of the number of connecting branches at baseline and in response to Pam3CSK4. The tube analysis was determined from 5 sequential fields (Magnification×40) focussing on the surface of the matrigel (n = 4). (C–D) The effect of Pam3CSK4 on angiopoietin-2 expression in HMVEC (n = 4) and RA synovial explants (n = 6). Data represented as the mean+/−sem. *p<0.05 significantly different from baseline. (E) Ang2, Tie2 and TLR2 expression in RA synovial tissue sections.

Article Snippet: The anti-TLR2 antibody was a kind gift from Opsona Therapeutics Ltd, The Trinity Centre for Health Sciences, Institute of Molecular Medicine, St James′ Hospital, Dublin, Ireland.

Techniques: Expressing

Journal: Nature Communications

Article Title: Label-free biosensor assay decodes the dynamics of Toll-like receptor signaling

doi: 10.1038/s41467-024-53770-9

Figure Lengend Snippet: a Schematic representation of TLR2 signaling, ligand priority and contact point of the two antagonists CU-CPT22 and C29. b HEK293 TLR2/1 or 2/6 reporter cells were stimulated with the indicated concentrations (ng/ml) of Pam 3 CSK 4 or Pam CSK 4 . Dashed lines represent the six time points that were used to generate concentration-effect curves ( c ). Baseline-corrected DMR recordings are mean + SEM and representative of three biologically independent experiments. c Sigmoidal concentration-effect curves resulting from DMR traces of n biologically independent experiments ( c : n = 3 biological replicates except Pam 3 CSK 4 log 3, log 2, log 1 n = 5, Pam CSK 4 log 0, 50 min n = 2) (Mean ± SEM). Concentration-effect curves of DMR data were generated by the response at six different time points ( b ). d HEK293 TLR2 reporter cells were stimulated with the indicated concentrations (ng/ml) of Pam 3 CSK 4 or Pam CSK 4 . HEK293 TLR2/1 or 2/6 reporter cells were preincubated with 50 µM of the TLR2 antagonist ( e ) CU-CPT22 or ( f ) C29 stimulated with the indicated concentrations (ng/ml) of Pam 3 CSK 4 or Pam CSK 4 . Calculated pharmacological parameters of the concentration-effect curves ( c ) are depicted in Table . Baseline-corrected DMR recordings are mean + SEM and representative of three biologically independent experiments. Source data are provided as a Source Data file. ( a ) was created in BioRender. Weindl, G. (2024) BioRender.com/q83w265.

Article Snippet: The TLR2 antagonist C29 was obtained from ChemDiv (San Diego, USA).

Techniques: Concentration Assay, Generated

Journal: Nature Communications

Article Title: Label-free biosensor assay decodes the dynamics of Toll-like receptor signaling

doi: 10.1038/s41467-024-53770-9

Figure Lengend Snippet: Pharmacological parameters of Pam 3 CSK 4 - and Pam 2 CSK 4 -induced DMR at six selected time points in HEK293 TLR2/1 and TLR2/6 reporter cells

Article Snippet: The TLR2 antagonist C29 was obtained from ChemDiv (San Diego, USA).

Techniques:

Journal: Nature Communications

Article Title: Label-free biosensor assay decodes the dynamics of Toll-like receptor signaling

doi: 10.1038/s41467-024-53770-9

Figure Lengend Snippet: a HaCaT cells were stimulated with LPS E. coli (1000 ng/ml), Pam 3 CSK 4 (1000 ng/ml) or Pam 2 CSK 4 (1000 ng/ml). b HEK293 TLR2/1 reporter cells were stimulated with Pam 3 CSK 4 (100 ng/ml) or Pam 2 CSK 4 (100 ng/ml). c HaCaT cells were preincubated with 50 µM of the TLR2 antagonists CU-CPT22 or C29 stimulated with Pam 3 CSK 4 (1000 ng/ml). Baseline-corrected DMR recordings are mean + SEM and representative of three biologically independent experiments. Source data are provided as a Source Data file.

Article Snippet: The TLR2 antagonist C29 was obtained from ChemDiv (San Diego, USA).

Techniques:

Journal: Autophagy

Article Title: Targeting autophagy in disease: established and new strategies

doi: 10.1080/15548627.2021.1936359

Figure Lengend Snippet: Biotech companies developing autophagy modulators to treat a range of diseases

Article Snippet: Neuropore Therapies , Activation , TLR2 antagonist (NPT520-34, NPT1220-312) and PI3K inhibitor (NPT520-337) targeting neurodegeneration..

Techniques: Activation Assay, Inhibition